mary jo fidler, md, fasco, comments on the outlook for immunotherapy combinations in sclc
Published 7 years ago • 32 plays • Length 0:39
Download video MP4
Download video MP3
Similar videos
-
2:24
mary jo fidler, md, fasco, offers opinion on integrating immunotherapies into treatment of sclc
-
1:15
mary jo fidler, md, fasco, considers the biomarker challenges when treating sclc
-
0:38
mary j. fidler, md, on combination lurbinectedin & checkpoint inhibitors in the treatment of sclc
-
0:49
mary j. fidler, md, considers whether lurbinectedin may improve outcomes in sclc
-
0:52
mary jo fidler, md, medical oncologist at rush
-
5:10
the spectrum of outcomes for small cell lung cancer
-
5:34
myelosupression help for lung cancer patients
-
5:33
cancer immune checkpoint inhibitors
-
1:17
dr. mary jo fidler on the role of oligoclonal t cell expansion in nsclc
-
0:59
mary j. fidler, md, provides opinion on the role of nivolumab ipilimumab in the treatment of nsclc
-
0:56
mary j. fidler, md, discusses the significance of the impower010 clinical trial
-
4:37
treating pd-l1-positive nsclc with immunotherapy alone vs chemoimmunotherapy
-
3:03
immunotherapy: new hope for lung cancer treatment
-
10:01
fda approvals in sclc and a biosimilar, and japanese approvals in aml, ntrk tumors, and more
-
1:51
refract: standard chemoimmunotherapy versus novel agents in r/r follicular lymphoma
-
2:12
crystal s. denlinger, md, facp
-
7:09
personalizing immunotherapy beyond pdl1 expression
-
27:33
cipo2015: optimizing adoptive immunotherapy for cancer
-
0:31
copy of dr. brahmer on the role of immunotherapy in metastatic nsclc
-
2:38
dr. jolene fisher, respirologist: working to improve healthcare for pulmonary fibrosis patients
-
13:30
cryobiopsy for ild diagnosis: is it time for a sea-change? | majid shafiq, md
-
1:41
dr. farago on eligibility criteria for frontline immunotherapy in sclc
Clip.africa.com - Privacy-policy